Compare ProShares Ultra Silver ETF (AGQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Regeneron Pharmaceuticals Inc — how do they compare? ProShares Ultra Silver ETF trades at $64.54, while Regeneron Pharmaceuticals Inc trades at $663.49 (market cap $70.90B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while ProShares Ultra Silver ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | REGN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $812.27 |
52-Week Low | $48.15 | $542.52 |
Market Cap | — | $70.90B |
Enterprise Value | — | $64.85B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) trades at $74.68, up 3.84% in the last session, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Recent news highlights significant volatility, including a 16% intraday crash on June 7, 2026, and concerns over beta slippage eroding silver's gains. The leveraged ETF structure amplifies both gains and losses, with silver prices facing headwinds from Federal Reserve rate expectations and import restrictions.
Outlook remains cautious due to AGQ's leveraged nature and silver market volatility. Investment opportunities exist if silver rallies, but risks include Fed policy impacts, technical bearish signals, and potential delivery squeezes. Analyst sentiment is mixed, with recent downgrades highlighting downside potential over the next 3-6 months.
Regeneron (REGN) trades at $676.23, up 3.36% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $9.47 exceeding the $8.91 forecast. Revenue grew to $14.34B in 2025, with a net income margin of 29.65%. Recent FDA acceptance of cemdisiran for gMG and inclusion in a manufacturing review pilot program highlight positive regulatory developments.
Outlook remains positive given earnings momentum and analyst consensus, but risks include regulatory scrutiny and competitive pressures. The consensus price target of $778.29 implies 15% upside, supported by 32 buy ratings and no sells. However, legal investigations and reliance on key drug portfolios warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
